Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Insmed (INSM) Misses Q4 EPS by 1c, Revenues Beat; Provides FY20 Sales Guidance
February 25, 2020 7:38 AM EST(Updated - February 25, 2020 8:09 AM EST)
(Update corrects headline to note revenue beat consensus)
Insmed (NASDAQ: INSM) reported Q4 EPS of ($0.59), $0.01 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $45.7 million versus the consensus estimate of $44.7 million.
Fourth Quarter and Full-Year 2019 Financial Results
Total revenue for the fourth quarter ended December 31, 2019 was $45.7 million, comprising U.S. net sales of $44.3 million and ex-U.S. net sales of $1.4 million. Total revenue for the full year 2019 was $136.5 million, comprising U.S. net sales of $132.1 million and ex-U.S. net... More